“…Tamiflu, also known as oseltamivir phosphate 1 is a potent chemotherapeutic agent for influenza treatment [ [1] , [2] , [3] ] Influenza is a severe viral infection of the respiratory system regarded as the most serious respiratory disease, which is responsible for significant morbidity and mortality due to both annual epidemics and predictable pandemics [ [1] , [2] , [3] ] More specifically, the avian influenza H5N1 has a mortality rate of about 60% [ 4 ] Unfortunately, little has been done to change the influenza infection patterns in past decades despite influenza being the most studied viral infection before the arrival of the human immunodeficiency virus (HIV) [ 5 , 6 ] Now in this global society, a highly aggressive strains of the influenza virus such as the H5N1 can mutate to become easily transmitted from human to human and spark another deadly pandemic just as with current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID19) pandemic, [ 7 , 8 ] which has brought the world to its knees. The surge in drug-resistant influenza strains resulting from naturally occurring mutations reminds us of the need for continued research to discover more potent neuraminidase inhibitors [ [9] , [10] , [11] , [12] , [13] ] The current anti-influenza drugs are useful templates in the development of new neuraminidase inhibitors through structure-activity relationship studies. As the research towards new and better treatment remains a top priority, it is equally important to improve the availability of the current anti-influenza drugs by developing better synthetic procedures to guard the world against influenza.…”